Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Alankrita Taneja's interest lie in hematological malignancies including lymphoma and multiple myeloma, with a special interest in cellular therapies. She also did a course in global and urban health equity while in residency and she is interested in health disparities and equitable care.

For more information, visit https://www.roswellpark.org/alankrita-taneja 

Blood Cancer OncTalk 2023 / Series number 5
Leading oncologists come together to discuss emerging treatment options and data regarding blood cancer, including multiple myeloma and lymphoma.
Author
Alankrita Taneja, Guest Faculty
Image
Blood Cancer OncTalk 2023

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Alankrita Taneja defines Smoldering Multiple Myeloma (SMM) and discusses how it differs from Multiple Myeloma (MM), risk factors and treatments.

 

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.